Drug Trial News

RSS

Pearl selects TransPerfect's Trial Interactive eTMF solution for clinical development programs

TransPerfect today announced that Pearl Therapeutics has implemented TransPerfect's Trial Interactive electronic Trial Master File (eTMF) solution for the company's clinical development programs.

23 Aug 2011

Spinifex secures AU$6.25 million in expanded Series B funding

Spinifex Pharmaceuticals, an Australian pain drug development company, today announced it has secured a further AU$6.25 million of venture capital investment from GBS Venture Partners Limited, Brandon Capital Partners Pty Limited, Uniseed Management Pty Limited and UniQuest Pty Limited to fund the development of its pain management drug, EMA401.

23 Aug 2011

Symphogen initiates Sym004 Phase 2 trial in squamous cell carcinoma of head and neck cancer

Symphogen A/S today announced the initiation of a Phase 2 clinical trial to investigate the safety and efficacy of Sym004 in patients who have failed anti-EGFR monoclonal antibody (mAb)-based therapy, with recurrent and/or metastatic squamous cell carcinoma of the head and neck.

23 Aug 2011

Living Cell Technologies xenoimplants first patients in Argentina trial

Living Cell Technologies Limited has implanted the first two patients taking part in a Phase II DIABECELL® clinical trial in Buenos Aires, Argentina.

22 Aug 2011

Researchers turn their attention to Chagas disease as developed countries see rise in infection rates

Chagas disease, a historically neglected tropical disease that the WHO estimates affects about 10 million people worldwide, is drawing increased attention as infection by the parasite spreads from Latin America to developed countries, such as Spain and the United States, Science reports.

20 Aug 2011

VOA News examines ethics of clinical drug testing in African nations

VOA News examines the ethics of conducting clinical drug trials in developing countries, particularly in Africa. Several international ethical frameworks outline guidelines for clinical trials, "including the World Medical Association's Declaration of Helsinki and the WHO's Good Clinical Practice Guidelines," but they are not mandatory, the news service writes.

19 Aug 2011

Time-release corticosteroid implant effective in treating uveitis

A team of researchers comparing the two leading treatment approaches for the eye condition uveitis, which is the fifth leading cause of blindness in the US, have found that a time-release corticosteroid implant placed surgically in the eye is similarly effective in treating the disease as anti-inflammatory corticosteroids and immunosuppressive drugs taken orally. The report was published online this week in the journal Ophthalmology.

19 Aug 2011

Amgen to present data from several Prolia studies at ASBMR 2011 meeting

Amgen today announced that it will present data from several Prolia (denosumab) studies, including eight year efficacy and safety data from a Phase 2 extension study in women with postmenopausal osteoporosis with low bone mineral density (BMD), at the 2011 American Society for Bone and Mineral Research (ASBMR) Annual Meeting in San Diego, Calif. from Sept. 16-20, 2011.

19 Aug 2011

NIH/NINDS awards AMRI to develop pre-clinical drug candidate for spinal muscular atrophy

AMRI today announced it received a federal contract award from the National Institutes of Health (NIH)/National Institute of Neurological Disorders and Stroke (NINDS) to provide chemistry and other drug discovery technologies in support of NINDS' Medicinal Chemistry for Neurotherapeutics Program (MCNP), part of the NIH Blueprint Neurotherapeutics Network.

19 Aug 2011

Minocycline, EDTA may combat catheter-related bacterial infections in dialysis patients

Antibiotics can help ward off serious bacterial infections in kidney disease patients who use tubes called catheters for their dialysis treatments. But if antibiotics are used too often, "super bugs" may crop up that are resistant to the drugs.

19 Aug 2011

FDA grants Fast Track designation for DARA's KRN5500 neuropathic pain relief drug

DARA BioSciences, Inc. announced today that its investigational drug KRN5500 has been granted Fast Track designation by the U.S. Food and Drug Administration (FDA) for the treatment of chemotherapy-induced neuropathic pain in patients with cancer.

19 Aug 2011

Antigen Express provides update on ongoing AE37 Phase 2 trial in breast cancer

Generex Biotechnology Corporation announced today that the Company's wholly-owned subsidiary Antigen Express, Inc. presented an update of the ongoing Phase 2 trial with an off-the-shelf immunotherapeutic cancer vaccine, AE37, in patients with breast cancer at Cambridge Healthtech Institute's Sixth Annual ImVacS: The Immunotherapeutics and Vaccine Summit held August 16-18, 2011 in Cambridge, MA.

19 Aug 2011

BTI completes SUGARDOWN human clinical study on blood sugar management

Boston Therapeutics, Inc. (BTI), a public company registered with the SEC and a developer of diabetes therapeutics, announced today the completion of a trial in healthy volunteers performed at the University of Sydney on SUGARDOWN, a dietary supplement designed to reduce post-meal elevation of blood glucose.

18 Aug 2011

New leukemia drug in early clinical testing offers some clues for better treatment

While testing a new drug designed to treat chronic leukemia, researchers at Cleveland Clinic discovered new markers that could identify which patients would receive maximum benefit from the treatment.

18 Aug 2011

FDA approves Mayo Clinic's ovarian and breast cancer vaccines

Mayo Clinic has received investigational new drug approval from the Food and Drug Administration for two new cancer vaccines that mobilize the body's defense mechanisms to destroy malignant cells.

18 Aug 2011

NCRM at Case Western Reserve to host stem cell conference in Cleveland

The National Center for Regenerative Medicine (NCRM) at Case Western Reserve University is proud to present "MSC 2011: Innovations in Cell-Based Regenerative Therapies," a three-day forum to highlight transformative breakthroughs in the area of adult stem cell medicine with a focus on how this research is being applied in patient care settings through innovative clinical trials.

18 Aug 2011

Clinical trials to evaluate and validate infrastructure of P-medicine consortium

Retrospective and prospective clinical trials will be run to evaluate and validate the infrastructure of the P-medicine consortium, announced a poster at the recent 3rd symposium of the Worldwide Innovative Networking in Personalized Cancer Medicine, held in Paris 6-8 July, 2011.

18 Aug 2011

Drug Trial News

Pearl selects TransPerfect's Trial Interactive eTMF solution for clinical development programs

Spinifex secures AU$6.25 million in expanded Series B funding

Symphogen initiates Sym004 Phase 2 trial in squamous cell carcinoma of head and neck cancer

Living Cell Technologies xenoimplants first patients in Argentina trial

Researchers turn their attention to Chagas disease as developed countries see rise in infection rates

VOA News examines ethics of clinical drug testing in African nations

Time-release corticosteroid implant effective in treating uveitis

Amgen to present data from several Prolia studies at ASBMR 2011 meeting

NIH/NINDS awards AMRI to develop pre-clinical drug candidate for spinal muscular atrophy

Minocycline, EDTA may combat catheter-related bacterial infections in dialysis patients

FDA grants Fast Track designation for DARA's KRN5500 neuropathic pain relief drug

Antigen Express provides update on ongoing AE37 Phase 2 trial in breast cancer

BTI completes SUGARDOWN human clinical study on blood sugar management

New leukemia drug in early clinical testing offers some clues for better treatment

FDA approves Mayo Clinic's ovarian and breast cancer vaccines

NCRM at Case Western Reserve to host stem cell conference in Cleveland

Clinical trials to evaluate and validate infrastructure of P-medicine consortium

Endo terminates collaboration and axomadol development program with Grunenthal

CEL-SCI receives Chinese patent for Multikine cancer drug

Enrollment commences in Allos' FOLOTYN Phase 3 trial for peripheral T-cell lymphoma

How agentic AI is reshaping laboratory workflows

Fourier 80: bringing benchtop NMR systems to the laboratory

How industrial hygiene flow calibration supports defensible exposure data

Latest News